top of page

Scientific Programme

Saturday, October 3, 2020


09.00                             Registration Opens


11.00 – 11.10              Welcome Address

                                         Michael von Bergwelt

11.10 – 13.30              Plenary Symposium 1: Emerging Concepts / New Agents

                                       Chair: Christoph Zielinski, NN


11.10 - 11.30                 Myeloid immune checkpoint inhibition 

                                        Timo K. van den Berg, Amsterdam, The Netherlands


11.30 - 11.50                 Potential of ADAR Pathway in immunotherapy

                                        Jeffrey Ishizuka, Boston, MA, USA


11.50 - 12.10                 The Stimulator of Interferon Genes (STING) pathway. Emerging clinical data 

                                        Reinhard Dummer, Zurich, Switzerland


12.10 - 12.30                  Neoadjuvant in melanoma: a new model for testing new strategies for improving efficacy

                                         Christian Blank, Amsterdam, The Netherlands


12.30 - 12.50                 CXCR3 required for anti-PD-1 efficacy

                                        Aleksandra Ozga, Boston, MA, USA


12.50 - 13.10                 IL-15 for cancer therapy

                                        Mark Rubinstein, Charleston, SC, USA


13.10 - 13.30                  T cell bispecific antibodies (4-1BB and tumor antigen)

                                         Pablo Umana, Zurich, Switzerland

13.30 – 14.30              Lunch


14.30 – 16.10              Plenary Symposium 2: Microbiome and immunotherapy

                                       Chair: Volkmar Nüssler, Giorgio Trinchieri

14.30 – 14.50                Microbiome and Immunotherapy in Cancer

                                        Giorgio Trinchieri, Bethesda, MD, USA

14.50 - 15.10                 Computational metagenomics for uncovering the unexplored microbiome diversity

                                        Nicola Segata, Trento, Italy

15.10 - 15.30                 Microbiome modulation for cancer therapy

                                      Hendrik Poeck, Munich, Germany

15.30 - 15.50                 Microbiome and epithelial cell stress in colon cancer

                                        Dirk Haller, Munich, Germany

15.50 - 16.10                 Microbiome modulation in HSC transplantation

                                        Marcel van den Brink, New York, NY, USA

16.10 – 16.40              Coffee Break


16.40 – 19.10              Plenary Symposium 3: Tumor microenvironment

                                        Chair: Eric Tartour, Jürgen Ruland

16.40 - 17.00                 The role of the microbiome in modulating the efficacy of anti-PD-1 therapy

                                        Vyara Matson, Chicago, IL, USA


17.00 - 17.20                Immunoscore as possible predictive marker of response to treatments

                                       Franck Pagès, Paris, France

17.20 - 17.40                Tumor intrinsic vs tumor extrinsic immune suppression 

                                       Kai Wucherpfennig, Boston, MA, USA


17.40 - 18.00                Arming oncolytic viruses for DC activation and recruitment in melanoma

                                       T.D. de Gruijl, Amsterdam, The Netherlands


18.00 - 18.20                Dissecting the interplay between tumor cells and the immune system in melanoma                                                       progression and response to therapy

                                       Marisol Soengas, Madrid, Spain


18.20 - 18.40                Pancreatic Cancer Tumor Microenvironment

                                       Lei Zheng, Baltimore, MD, USA


18.40 - 18.55                O1 - Tumor lactic acidosis alters decisive T cell activities

                                       Angelika Fischbeck, Munich, Germany


18.55 - 19.10                O2 - TGF-beta blocks type I IFN release and tumor rejection in spontaneous mammary


                                       Nadege Bercovici, Paris, France


19.10 – 20.45            Welcome Reception and Poster Viewing (at the venue)

Sunday, October 4, 2020


08.30 – 09.30             Plenary Symposium 4: Vaccine Therapy

                                      Chair: Lei Zheng, Barbara Seliger

08.30 - 08.50                Mucosal vaccinations for cancer treatment 

                                      Georg Stary, Vienna, Austria


08.50 - 09.10                Multiple antigen-engineered DC vaccines promoting antitumor immunity in melanoma

                                       Lisa Butterfield, San Francisco, CA, USA


09.10 - 09.30                Vaccine therapy in reversing anti -PD1 resistance

                                       Samir Khleif, Washington, DC, USA


09.30 – 10.30            Pro & Contra Session:

                                     Blinatumomab vs anti-CD19 CAR T cells: which treatment should be preferred and when?

                                       Can we treat with either regimen after relapse on the other?

                                     Chair: Dominik Wolf

09.30 – 10.00               Pro Bite

                                       Max Topp, Würzburg, Germany

10.00 – 10.30               Pro CAR

                                       Marion Subklewe, Munich, Germany

10.30 – 11.00             Coffee Break


11.00 – 12.30             Plenary Symposium 5: Precision Medicine Meets Immunotherapy (Immuno-Monitoring)

                                      Chair: Lisa Butterfield, José Saro

11.00 – 11.20               High dimensional Immune Monitoring of Clinical Trials to Advance Human Immunotherapy

                                       Pier Federico Gherardini, San Francisco, CA, USA


11.20 – 11.40               Hyperprogressive disease in patients treated with Immune checkpoint inhibitors

                                       Giuseppe Lo Russo, Milan, Italy


11.40 - 12.00                Novel splice isoforms, target for immunotherapy

                                       Jacques Banchereau, Bar Harbor, ME, USA


12.00 – 12.15               O3 - Local and systemic immunological effects of IORT in breast cancer patients after breast-

                                     conserving surgery

                                       Roman, Hennel, Munich, Germany

12.15 – 12.30               O4 - Directly Linking Single T Cell Phenotype and Function to Genotype

                                       Yelena Bronevetsky, Emeryville, United States


12.30 – 14.00             Lunch

14.00 – 15.00             Satellite Symposium

                                       Please click HERE to view the detailed programme

15.00 – 15.45             Lifetime Achievement Award

                                      Chair: Michael von Bergwelt

                                        The 34th anniversary of interleukin 6; a major player in inflammation, autoimmunity and


                                        Toshio Hirano, Chiba, Japan

15.45 – 16.15             Coffee Break

16.15 – 17.10             Plenary Symposium 6: “Lost in Translation”

                                        Chair: Philipp Beckhove, Hendrik Poeck

16.15 – 16.35               Ups and downs of IDO inhibition in cancer treatment

                                       George Prendergast, Philadelphia, PA, USA

16.35 – 16.55               Why adoptive T cell therapies fail solid tumors?

                                       Sebastian Kobold, Munich, Germany

16.55 – 17.10               O5 - Mechanisms of lung cancer hyper-progression promoted by PD-1 immune checkpoint


                                       Amaia Martinez-Usatorre, Lausanne, Switzerland


17.10 – 18.10              Plenary Symposium 7: Young Researcher Session

                                        Chair: Sebastian Kobold, Lisa Butterfield


17.10 – 17.25               O6 - In vivo live imaging of human T/B cell lymphoma cross-linking mediated by bispecific

                                     CD20-TCB antibody

                                       Floriana Cremasco, Schlieren, Switzerland

17.25 – 17.40               O7 - Update of the OpACIN and OpACIN-neo trials: 36-months and 18-months relapse-free

                                     survival after (neo)adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma


                                       Judith Versluis, Amsterdam, The Netherlands

17.40 – 17.55               O8 - RIG-I activation enhances melanoma immunogenicity and improves anti-tumor T cell

                                     responses in combination with anti-PD-1 immune checkpoint blocking antibodies

                                       Beatrice Thier, Essen, Germany

17.55 - 18.10                O9 - Deconstruction of hampered dendritic cell development by micro-environmental cross-

                                     talk in an organotypic human melanoma-in-skin model

                                       Marta Lopez Gonzalez, Amsterdam, The Netherlands


19.30                            ITOC7 Conference Dinner


Monday, October 5, 2020


08.00 – 09.05              Plenary Symposium 8: Cell Therapy in Solid Tumors

                                      Chair: Christian Blank, Pedro Romero

08.00 – 08.20                Challenges of T-cell therapy in solid tumors

                                        Cassian Yee, Houston, TX, USA


08.20 – 08.35                Novel CAR formats for solid tumors 


08.35 – 08.50                Novel strategies to enable T cell therapy of cancer

                                        Per Thor Straten, Herlev, Denmark


08.50 – 09.05                CAR T cell therapy in non hematological pediatric cancer

                                        Franco Locatelli, Rome, Italy


09.05 – 10.20             Plenary Symposium 9: Cell Therapy in Haematologic Diseases

                                      Chair: Hinrich Abken, Florian Bassermann

09.05 – 09.25                Cell therapy of hematological malignancies

                                        Chiara Bonini, Milan, Italy


09.25 – 09.45                New targets and technologies for CAR-T

                                        Michael Hudecek, Würzburg, Germany


09.45 – 10.05                Genome edited T cells for leukaemia

                                        Waseem Quasim, London, United Kingdom


10.05 - 10.20                 O10 - Synthetic agonistic receptor-activating BiTEs - a modular platform for the efficient

                                      targeting of acute myeloid leukemia

                                        Mohamaed-Reda Benmebarek, Munich, Germany


10.20 – 10.50              Coffee Break


10.50 – 13.15              Plenary Symposium 10: Combination Therapy

                                      Chair: Samir Khleif, Michael Bergmann

10.50 – 11.10                 Combination of innate immune stimulation with immune check point blockade for 

                                       cancer therapy

                                         Simon Heidegger, Munich, Germany


11.10 - 11.30                  Chemotherapy and antiPD-1 neoadjuvant Triple negative breast Cancer

                                         Marleen Kok, Amsterdam, The Netherlands


11.30 - 11.50                  Targeting the tumour microenvironment through co-neutralization of IL-1beta and PD-1 to                                           attenuate MRD

                                         Ron-Nathan Apte, Beer Sheva, Israel

11.50 - 12.10                  Targeting immunosuppressive adenosine pathway in cancer 

                                         Rakesh Kumar, Gaithersburg, MD, USA

12.10 - 12.30                  GARP-directed cancer immunotherapy: mechanisms and opportunities

                                         Claus Belka, Munich, Germany

12.30 – 12.45                 O11 - Expression of anti-apoptotic gene cFLIP to enhance persistence in CAR T cells

                                         Grace Tan, North Dunedin, New Zealand

12.45 - 13.00                  O12 - A bispecific VHH approach to leverage the potent and widely applicable tumor

                                       cytolytic capacity of Vγ9Vδ2 T cells

                                         Lisa King, Amsterdam, The Netherlands

13.00 - 13.15                 O13 - Gemcitabine induces pro-apoptotic BH3 only proteins and sensitizes pancreatic ductal

                                      adenocarcinoma cells for RLH-triggered immunogenic cell death

                                         Philipp Metzger, Munich, Germany


13.15 - 13.30               Best Poster Awards & Closing Remarks

                                       Chair: Volkmar Nüssler

13.30 - 14.30               Lunch & Farewell


Emerging concepts / novel agents


A Phase 1a/1b Dose-escalation Study of Intravenously Administered SB 11285 Alone and in Combination with Nivolumab in Patients with Advanced Solid Tumors

Atif Abbas, Hopkinton, United States


HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer

Yan Asmann, Jacksonville, United States



VOC Pattern Recognition of Lung Cancer: a Comparative Evaluation of Different Dog- and eNose-Based Strategies Using Different Sampling Materials

Wiebke Biehl, Munich, Germany



A spatially resolved, highly multiplexed biomarker analysis pipeline that bridges the divide between discovery and clinical research.

Oliver Braubach, Menlo Park, United States



Development of signal amplification for spatially-resolved, highly multiplexed biomarker analysis of human tumor tissues.

Oliver Braubach, Menlo Park, United States


Spatially-resolved, highly multiplexed biomarker analysis of cancerous and normal human breast tissues.

Oliver Braubach, Menlo Park, United States




Targeting a membrane proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on tumor cells

Eric Hatterer, Plan les ouates -  Geneva, Switzerland


Beyond PD-1: Characterization of new checkpoints restricting function of cytotoxic lymphocytes infiltrating human carcinoma

Anna Herbstritt, München, Germany



Dual signalling protein 107 triggers innate and adaptive immune response towards tumour cells

Lisa Jacob, Groningen, Netherlands



IFNy secretion of adaptive and innate immune cells as a parameter to display leukaemia derived dendritic cell (DCleu) mediated immune responses in AML

Lara Klauer, Munich, Germany


Immunomodulation of blasts with clinically approved response modifiers to improve antileukemic T-cell reactivity in AML: an ex vivo simulation of the clinical situation

Christoph Kugler, Munich, Germany


Role of Exosomes as promotors or biomarkers to study activation of leukemia-derived dendritic cells (DCleu)-mediated antileukemic activation of adaptive and innate immune-reactive cells against AML-blasts

lin li, munich, Germany






MERTK signaling is critical for T cell proliferation and memory

Richard Powell, Herlev, Denmark


Excessive biological ageing of circulating neutrophils in cancer promotes tumor progression

Christoph Reichel, Munich, Germany


Personalized combination of neoadjuvant domatinostat, nivolumab (NIVO) and ipilimumab (IPI) in macroscopic stage III melanoma patients stratified according to interferon-gamma (IFN-gamma) signature - the DONIMI study

Irene Reijers, Amsterdam, Netherlands


Effects of the STAT3 inhibitors on senescent tumour cells

Olena Sapega, Prague, Czech Republic




Tim-3/Galectin-9 pathway controls the ability of malignant cells to escape host immune surveillance. Regulatory mechanisms and therapeutic targets

Vadim Sumbayev, Chatham Maritime, United Kingdom


Metabolic status and immune activation influence clinical outcomes in patients after allogeneic hematopoietic stem cell transplantation

Sebastian Theurich, Munich, Germany


‘Kit’-mediated blastmodulation to leukemia-derived DC significantly improves antileukemic activities in whole blood independent of AML-patients’ subtypes

Selda Ugur, Munich, Germany


Tim-3-galectin-9 immunosuppressive pathway in human liquid and solid tumours

Inna Yasinska, Chatham Maritime, United Kingdom

Microbiome and immune system/immunotherapy


Predictive impact of the gut microbiota on treatment response to CD19 specific CAR T-cells

Viktoria Blumenberg, Munich, Germany




Generating neo- and self-antigen screening libraries for class II HLA presentation

Veronica Pinamonti, Heidelberg, Germany


Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma

Elena Staib, Köln, Germany

Tumor microenvironment





Prevalence of CD112R+ immune cells in normal lymphatic tissues, inflammation and the cancer microenvironment

Niclas Blessin, Hamburg, Germany


A reference transcriptomic map of tumor-infiltrating T cells

Santiago Carmona, Epalinges, Switzerland


The immune contexture has an impact on platinum sensitivity in primary and metastatic ovarian cancer

Katharina Dötzer, Munich, Germany


Suppression of T-cell proliferation and cytokine release by the adenosine axis are mediated by different mechanisms

Julia Festag, PLANEGG/ MARTINSRIED, Germany


Organization, function and gene expression of tertiary lymphoid structures in PDAC resembles lymphoid follicles in secondary lymphoid organs

María García-Márquez, Cologne, Germany


Applying Multispectral Unmixing and Spatial Analyses to Explore Tumor Heterogeneity with a Pre-Optimized 7-color Immuno-Oncology Workflow

Virginie goubert, Marlborough, United States


Deep Spatial Profiling of the Immune Landscape of MSI and MSS Colorectal Tumors

Mathias Holpert, Seattle, United States


Pattern of Ki67+ expanding CD8+ cytotoxic T cells in healthy tissues, inflammation and the cancer microenvironment

Claudia Hube-Magg, Hamburg, Germany


In Vitro Functional Bioassays using suppressive macrophages, MDSC and exhausted T cells to evaluate Candidate Therapeutic Effectiveness in Immuno-Oncology

Thibaut Janss, Gosselies, Belgium


Fast automated microfluidic-based multiplexed immunofluorescence for tumor microenvironment analysis

Alexandre Kehren, Lausanne, Switzerland




Omental fat in ovarian cancer potentially induces lymphangiogenesis

Benedicte Lenoir, Heidelberg, Germany


Immune activation underlies clinical response to intravesical BCG immunotherapy in non-muscle invasive bladder cancer

Chun Lim, Singapore, Singapore


Prevalence and prognostic role of FoxP3<sup>+</sup>regulatory T lymphocytes in cancer. A tissue microarray study on >20’000 cancers

Tim Mandelkow, Hamburg, Germany




Exploring tumor-intrinsic factors regulating the recruitment of myeloid-derived suppressor cells (MDSC) in pancreatic ductal adenocarcinoma

Carlotta Rambuscheck, München, Germany


Immunophenotyping of liver and lung metastases in colorectal cancer

Friederike Schlüter, Munich, Germany


Predicting tumor specific outcome from a highly differential analysis of circulating immune cells in hepatocellular carcinoma patients after surgery

Markus Schoenberg, Munich, Germany


Age-induced changes in anti-tumor immunity alter the tumor immune infiltrate and reduce response to immune-oncology treatments

Suzanne Sitnikova, Cambridge, United Kingdom


Preclinical Case Study: Patient-derived head and neck cancer xenograft on mice humanized with autologous immune cells, a model for personalized immuno-oncology research

Maria Stecklum, Berlin, Germany




Site-specific immune evasion and substantial heterogeneity within entities provide evidence for personalized immunotherapy

Martin Thelen, 50931, Germany


Functional Defects in B-cells of Patients with von-Hippel-Lindau Syndrome

Sebastian Theurich, Munich, Germany


uPA-PAI-1 heteromers promote advanced stages of breast cancer by attracting pro-tumorigenic neutrophils

Bernd Uhl, München, Germany


Solid cancers possess increased CD86+ antigen-presenting B cells that induce tumor antigen-specific T cell responses in vitro

Kerstin Wennhold, Cologne, Germany


Evaluation of immunogenicity differences in LLC1 and GL261 tumor models for effective chemo-immunotherapy treatment

Karolina Zilionyte, Vilnius, Lithuania

Vaccine Therapy


Dendritic-cell based immunotherapy targeting pancreatic and NSCLC cancer stem cells

João Calmeiro, Coimbra, Portugal


A novel Cancer immunotherapy combines rMVA-CD40L with tumor targeting antibodies

Maria Hinterberger, Martinsried, Germany


Immune modulatory vaccine directed against IDO1-expressing immune cells elicits T cell-mediated anti-tumor immunity and enhances anti-PD1 responses

Ayako Pedersen, Copenhagen, Denmark


Multifunctional antibody construct for in vivo targeting of dendritic cells as a therapeutic vaccination strategy in AML

Saskia Schmitt, München, Germany


The CXCR3/CXCL10 axis promotes the terminal differentiation of TCF1+ T cells in persistent viral infection

Aleksandra Ozga, Boston, MA, USA

Precision Medicine Meets Immunotherapy (Immuno-Monitoring)


Correlation of survival with alterations in peripheral T cell subsets, T cell activation markers and immune checkpoint molecules in advanced pancreatic cancer patients receiving FOLFIRINOX or gemcitabine + nab-paclitaxel.

Stephan Kruger, Munich, Germany


Comparative analysis of RNA versus DNA as input material for IGH repertoire sequencing panels for immuno-oncology applications and rare clone detection

Geoffrey Lowman, Carlsbad, United States


Cell Therapy in Solid Tumors


Bispecific antibody-driven synthetic agonistic receptor - transduced T cells mediate specific and conditional therapy in melanoma cancer models

Mohmaed-Reda Benmebarek, Munich, Germany


Auto-inducible promoters to improve CAR T cell efficacy and patient safety in solid tumor treatment

Hannah Goy, Dunedin, New Zealand


Enhancing CAR T cell persistence and memory through modulating mitochondrial function

Grace Tan, Dunedin, New Zealand


C-C chemokine receptor 8 tumor-directed recruitment enables CAR T cells to reject solid tumors

Bruno L. Cadilha, München, Germany




Clinical considerations for chimeric antigen receptor (CAR) T cell therapies --- a regulatory perspective

Ke Liu, SILVER SPRING, United States


Optimising inducible and constitutive promoters for driving long RNA encoding chimeric antigen receptors (CAR) and accessory genes

Alexander McLellan, Dunedin, New Zealand


Enhancing T cell function for cancer immunotherapy by microRNA mediated knockdown of PRKAR1A

Aarati Poudel, Dunedin, New Zealand


IDO1-deleted CAR T cells show improved therapeutic efficacy in murine pancreatic cancer models

Anne Senz, München, Germany


Adoptive cell therapy of triple negative breast cancer with redirected Cytokine-Induced Killer cells

Roberta Sommaggio, Padova, Italy


CXCR6 expression enhances accumulation of anti-mesothelin CAR T cells at the tumor site and their therapeutic efficacy in pancreatic cancer xenografts

Stefan Stoiber, Munich, Germany


Immunomodulatory biomarkers in neoadjuvant chemotherapy of breast cancer

Kerstin Wimmer, Vienna, Austria


Anti-hPSMA CAR engineered NK-92 cells: An off-the-shelf cellular therapeutic for targeted elimination of prostate cancer cells

Gaia Zuccolotto, Padova, Italy




Cell Therapy in Haematologic Diseases


CD19 CAR T-cells for relapsed/refractory Diffuse Large B-Cell Lymphoma: Real-world data from LMU Munich

Veit Bücklein, Munich, Germany


High-affinity TCRs specific for Cancer Testis Antigens as a therapy for multiple myeloma and solid tumors

Natasa Prokopi, Leiden, Netherlands


Combination Therapy






New strategy for the treatment of acute myeloid leukemia by combining specific CD33 tumor targeting with CD47-SIRPa immune checkpoint blockade

Markus Eisele, Munich, Germany


Low-dose Checkpoint inhibitors with hyperthermia and IL-2 are safe and effective in stage IV cancer with unfavorable immunological profile (MSI low, PD-L1 under 1%, TMB low) - A single-institution experience from 2015 to 2020

Ralf Kleef, Vienna, Austria


Photo therapy with cancer-specific nanoporphyrin potentiates immunotherapy in bladder cancer

Chong-xian Pan, Sacramento, United States



Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy

Charlotte Pilard, Liège, Belgium


Young Researchers Session





CCL18 modulates the immunological microenvironment in ovarian carcinoma

Sangya Chatterjee, Heidelberg, Germany


Adoptive cell therapy of hematological malignancies using Cytokine-Induced Killer cells retargeted with monoclonal antibodies

Anna Dalla Pietà, Padua, Italy


A novel universal CAR-T cell platform based on the P329G mutation in therapeutic IgG1 antibodies

Diana Darowski, Schlieren, Switzerland


Uveitis caused by new tumor treatments

Hendrik Engelke, Munich, Germany


Mapping and tackling tumor and chemotherapy-induced immune suppression in breast cancer sentinel lymph nodes

Marijne Heeren, Amsterdam, Netherlands


Cathepsin S alterations induce a tumor-promoting immune microenvironment in follicular lymphoma

Johannes Hildebrand, Munich, Germany


Oncolytic H5N1 influenza strain displays superior therapeutic properties independent of immuno-stimulatory interleukin-2 transgene expression

Julijan Kabiljo, Vienna, Austria


Immunogenicity induced by the academic Chimeric Antigen Receptor CAR19 (ARI-0001) in patients with CD19-positive relapsed/refractory B-cell malignancies recruited into the CART19-BE-01 clinical trial

Nela Klein-González, Barcelona, Spain


'An enhanced CRISPR tool for treating chronic myelogenous leukemia'

Duško Lainšček, Ljubljana, Slovenia


An immune modulatory vaccine targeting CCL22 promotes anti-tumor immunity

Inés Lecoq, København, Denmark


Clinical-grade manufacturing of ROR1 CAR T cells using a novel virus-free protocol

Katrin Mestermann, Würzburg, Germany


PD-1 checkpoint blockade for treatment of mucormycosis and invasive aspergillosis in a stem cell transplant recipient

Niklas Mueller, Munich, Germany


Targeting the stroma to enhance effector memory T cell infiltration and anti-tumor response to anti-PD1 antibody in pancreatic ductal adenocarcinoma

Arsen Osipov, Baltimore, United States




Hematotoxicity and Infectious Complications of CD19 CAR-T cell treated patients: Real-life data from the LMU Munich

Kai Rejeski, München, Germany


Optimization of anti-nucleolin single-domain antibody against triple negative breast cancer

Rita Ribeiro, Coimbra, Portugal


Local immunotherapy of brain cancer harnessing high-retention Fc-fusion constructs

Linda Schellhammer, Schlieren, Switzerland


TLR3 suppresses colorectal carcinogenesis, presumably through up-regulation of T-cell attracting CXC chemokines

Anna Sichler, München, Germany




Bifunctional SIRPα-CD123 fusion antibody for the elimination of acute myeloid leukemia stem cells

Siret Tahk, Munich, Germany


Optimization of a GMP-grade large-scale expansion protocol for Cytokine-Induced Killer cells using gas-permeable static culture flasks.

Annavera Ventura, Padua, Italy



bottom of page